Meanwhile, serum levels of ULBP2 was positively correlated with ADAM10 expression shown by immunohistochemistry, suggesting that gemcitabine may exerts its anti-tumor effect through inhibition of ADAM10 mediated ULBP2 shedding and corresponding enhanced NKG2D-mediated tumor elimination. Here, KLRK1 is linked to neoplasm.